Links

Homepage

Stock List

Search by Ticker

News

Login

Nektar Therapeutics (NASDAQ:NKTR)
Stock Analysis

NKTR20.1
▼ -1.47%-0.3

Stock Analysis

The following stock analysis is based on 7.7 years of data (i.e. since Nov 20, 2012). All the stock history has been downloaded.

Stock Exchange

Nektar Therapeutics trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Nektar Therapeutics

It is currently trading at $20.1 ($20.4 the previous day).

Financials

The next reporting date is in 83 days (2020 11 04).

The current Canada / US exchange rate is 1.3244.



Over the past 12 months, $259200 worth of shares have been purchased and $7701413 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 12.6% per year assuming steady exponential growth. The actual 5 year average is 40.7. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year19.925420560748-50.5- Below Average
2 year40.285421686747-33.5- Below Average
3 year60.554058577406260.2+ Above Average
4 year16.81297959183720.1- Below Average
5 year14.0013307984797.2- Below Average
Nektar Therapeutics is projected by analysts to get to $26.00 within the next 12 months (29.4%), but preticted targets range from as high as $43.00 (113.9%) and as low as $18(-10.4%).

Risk

The worst drop it has had in recent years is -86.7%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
1023.27DROPPING
3023.52DROPPING
6022.27RISING
15015.54RISING
36518.58DROPPING
80090.35DROPPING
120018.97RISING
160012.71RISING
200013.65DROPPING


With an average increase of 12.6% year over year, if Nektar Therapeutics is bought at the worst time, Stockmarketizer analysts estimate it will take 82.6 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ?

Wed, 12 Aug 2020 13:42:35 At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund ...... Read Full Article

Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck

Wed, 12 Aug 2020 12:00:00 Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektarand's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibodyand's personalized neoantigen ...... Read Full Article

Nektarand's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

Fri, 07 Aug 2020 15:35:03 Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.... Read Full Article

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Thu, 06 Aug 2020 23:00:11 Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Nektar Therapeutics Reports Second Quarter 2020 Financial Results

Thu, 06 Aug 2020 20:15:00 Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.... Read Full Article

If You Had Bought Nektar Therapeutics (NASDAQ:NKTR) Stock Five Years Ago, You Could Pocket A 106% Gain Today

Wed, 05 Aug 2020 15:15:55 When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...... Read Full Article

Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline

Thu, 30 Jul 2020 16:33:04 Nektar (NKTR) doesnand't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article

Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets

Tue, 28 Jul 2020 22:00:00 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the ...... Read Full Article

Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)

Wed, 24 Jun 2020 01:46:51 The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isnand't the intention, these filings to a ...... Read Full Article

Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT

Mon, 15 Jun 2020 01:25:45 Q1 2020 Nektar Therapeutics Earnings Call... Read Full Article

Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?

Sat, 06 Jun 2020 15:31:03 Nektar (NKTR) reported earnings 30 days ago. Whatand's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

Thu, 04 Jun 2020 21:00:00 Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune ...... Read Full Article

7 Stocks Maverick Capital Continues to Buy

Tue, 26 May 2020 15:11:35 Adobe and Avantor make the list Continue reading...... Read Full Article

Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in and'Cancer Discoveryand' Journal

Fri, 22 May 2020 12:30:00 Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data ...... Read Full Article

Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics

Sun, 17 May 2020 23:13:01 Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.... Read Full Article

Nektarand's (NKTR) Q1 Earnings and Revenues Top Estimates

Fri, 08 May 2020 14:29:02 Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.... Read Full Article

No Surprises in Nektarand's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials

Fri, 08 May 2020 07:57:00 ... Read Full Article

Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript

Fri, 08 May 2020 07:31:06 NKTR earnings call for the period ending March 31, 2020.... Read Full Article

Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets

Tue, 28 Apr 2020 21:00:00 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the ...... Read Full Article
<